CG Oncology Stock Price Target Lowered by Royal Bank of Canada

CG Oncology's stock price has been lowered by research analysts at Royal Bank of Canada from $81.00 to $79.00, with a potential upside of 6.59% from its previous close.

The firm currently holds an 'outperform' rating on the stock, and this is not the only update for CG Oncology's price target as other analysts have weighed in on the company.

Piper Sandler increased their target price on shares of CG Oncology from $82.00 to $85.00 and gave the stock an 'overweight' rating in a research report, while Truist Financial lifted their price objective on CG Oncology from $82.00 to $85.00 and gave the company a 'buy' rating.

HC Wainwright restated a 'buy' rating and issued a $100.00 price target on shares of CG Oncology in a report, but trimmed its FY2029 EPS forecast to $2.34 from $2.43, partially offsetting its more optimistic FY2030 estimate.